Free Trial
ASX:AMT

Allegra Medical Technologies (AMT) Stock Price, News & Analysis

Allegra Medical Technologies logo

About Allegra Medical Technologies Stock (ASX:AMT)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
N/A
Market Capitalization
$3.47 million
P/E Ratio
N/A
Dividend Yield
8.63%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Allegra Medical Technologies Limited designs, sells, and distributes medical device products in Australia. The company provides adult and adolescent clavicle fixation systems; a range of symmetrical and asymmetrical offsets for shoulder; and StripEase, ChiroKlip, distal radius systems, compression screws, hand fracture systems, ulna shortening plates, and modular ceramic or CoCr heads for heads. It also offers reconstruction prosthesis, modular tumor and revision system, partial pelvis replacement, standard C cementless stem, revision cup, hip acetabular cup system, IP acetabular cup, ceramic prosthesis heads, and CoCrMo prosthesis heads, as well as cemented femoral stem, unipolar head, and cup resector; ActiveKnee, a total knee replacement prosthesis and knee distal first instruments, femoral condyle, nanofracture, arthrodesis nail, modular knee, rotational and hinge knee, and uni knee; and foot and ankle products, such as total ankle replacement systems, DF toe, A-curve handles, screws, activ fuse, and plating system. In addition, the company provides sawblades and kirschner wires and pins. Further, it offers NanoFx, a solution for microfracture procedure; and instrument sets, including post-surgery rehabilitation, shoulder surgery, direct anterior approach, PCL protector, and revision surgery instrument. The company was formerly known as Allegra Orthopaedics Limited and changed its name to Allegra Medical Technologies Limited in November 2023. Allegra Medical Technologies Limited was incorporated in 1994 and is based in Lane Cove West, Australia.

Receive AMT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Allegra Medical Technologies and its competitors with MarketBeat's FREE daily newsletter.

AMT Stock News Headlines

2024 Best Medical Schools: Research
While others chase AI stocks, smart traders do this
Since the pandemic, the average mortgage payment has jumped from $1,427 to $2,047. That's an extra $600 every single month just vanishing from people's pockets. Meanwhile, credit card debt is hitting record highs, and savings accounts are at their lowest since 2008. Most folks are left with two options… Get a second job... or work overtime on weekends. But what if there was a third option? I just uncovered a shocking anomaly in the options market that could change everything... One that lets you target extra cash on days when most people make nothing - weekends. Think what that could mean for your monthly budget...
Allegra Medical Technologies Ltd
Allegra Medical Technologies Limited (AMT.AX)
Allegra Medical Technologies Ltd AMT
See More Headlines

AMT Stock Analysis - Frequently Asked Questions

Based on aggregate information from My MarketBeat watchlists, some other companies that Allegra Medical Technologies investors own include AbbVie (ABBV), Mastercard (MA), Trade Desk (TTD), Exxon Mobil (XOM), Abbott Laboratories (ABT), Broadcom (AVGO) and CrowdStrike (CRWD).

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Medical Devices
Sub-Industry
Trading
Current Symbol
ASX:AMT
CIK
N/A
Fax
N/A
Employees
6,390
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$2.69 million
Net Margins
-527.67%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.70 million
Price / Cash Flow
N/A
Book Value
A($0.01) per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$3.47 million
Optionable
Not Optionable
Beta
0.85
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (ASX:AMT) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners